John Higgins Net Worth

The estimated Net Worth of John L Higgins is at least $37.4 Milione dollars as of 8 July 2024. Mr. Higgins owns over 6,000 units of Ligand Pharmaceuticals stock worth over $4,392,459 and over the last 20 years he sold LGND stock worth over $26,231,644. In addition, he makes $6,770,380 as Chief Executive Officer e Director at Ligand Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Higgins LGND stock SEC Form 4 insiders trading

John has made over 54 trades of the Ligand Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 6,000 units of LGND stock worth $137,700 on 8 July 2024.

The largest trade he's ever made was exercising 120,000 units of Ligand Pharmaceuticals stock on 25 January 2021 worth over $1,959,600. On average, John trades about 6,204 units every 50 days since 2004. As of 8 July 2024 he still owns at least 42,608 units of Ligand Pharmaceuticals stock.

You can see the complete history of Mr. Higgins stock trades at the bottom of the page.

John Higgins biography

John L. Higgins serves as Chief Executive Officer, Director of the Company. Prior to joining our company, Mr. Higgins served as Chief Financial Officer at Connetics Corporation, a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals. Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves on the board, audit committee and nominations & governance committee of Bio-Techne Corporation, a publicly-traded life sciences services. Mr. Higgins has served as a director on numerous public and private companies. He graduated Magna Cum Laude from Colgate University with an A.B. in economics. Mr. Higgins’ executive experience operating and managing public biotechnology companies, his prior service on other company boards and his financial transaction experience as an investment banker in the biopharmaceutical industry contributed to our board of directors’ conclusion that he should serve as a director of our company.

What is the salary of John Higgins?

As the Chief Executive Officer e Director of Ligand Pharmaceuticals, the total compensation of John Higgins at Ligand Pharmaceuticals is $6,770,380. There are no executives at Ligand Pharmaceuticals getting paid more.

How old is John Higgins?

John Higgins is 50, he's been the Chief Executive Officer e Director of Ligand Pharmaceuticals since 2015. There are 11 older and 6 younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals, Inc. is John Lamattina, 70, who is the Independent Director.

What's John Higgins's mailing address?

John's mailing address filed with the SEC is 614, Northeast McKinley Place, Minneapolis, Hennepin County, Minnesota, 55413, United States.

Insiders trading at Ligand Pharmaceuticals

Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... e Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.

What does Ligand Pharmaceuticals do?

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.

Complete history of Mr. Higgins stock trades at Biocryst Pharmaceuticals, Bio-Techne Corp e Ligand Pharmaceuticals

Ligand Pharmaceuticals executives and stock owners

Ligand Pharmaceuticals executives and other stock owners filed with the SEC include:

• John Higgins,
  Chief Executive Officer, Director
• Matthew Foehr,
  President, Chief Operating Officer
• Matthew Korenberg,
  Chief Financial Officer, Executive Vice President - Finance
• Charles Berkman,
  Senior Vice President, General Counsel, Secretary
• John L. Higgins,
  CEO & Exec. Director
• Matthew W. Foehr,
  Pres & COO
• Matthew E. Korenberg,
  Exec. VP of Fin. & CFO
• Charles S. Berkman J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Charles S. Berkman,
  Sr. VP, Gen. Counsel & Sec.
• Sarah Boyce,
  Independent Director
• John Kozarich,
  Non-Executive Independent Chairman of the Board
• Stephen Sabba,
  Independent Director
• Jason Aryeh,
  Independent Director
• Todd Davis,
  Independent Director
• Sunil Patel,
  Independent Director
• Nancy Gray,
  Independent Director
• John Lamattina,
  Independent Director
• Simon Latimer,
  Head of Investor Relations
• Patrick Lucy,
  Sr. VP & CBO Protein Expression Bus.
• Dr. Vincent D. Antle,
  Sr. VP of Technical Operations & QA - Capitsol
• Dr. Keith Marschke,
  Sr. VP of Biology & Scientific Affairs
• Audrey Warfield-Graham,
  Sr. VP of HR
• Todd Pettingill,
  Director of Corp. Devel.
• Patrick O'Brien,
  Sr. VP of Investor Relations
• Jason Haas,
  Director
• Corp Plc Elan,
  10% owner
• Andres Negro Vilar,
  Exe V-P, R & D, CSO
• Partners L P/Ilbiotechnolog...,
  
• Bruce Peacock,
  Director
• Zofia E Dziewanowska,
  VP, Clinical Research
• Partners L P/Ilbiotechnolog...,
  
• Melanie J Herman,
  Director of Accounting
• Nishan M De Silva,
  VP, Corporate Development
• David M Knott,
  10% owner
• Syed Kazmi,
  VP, Bus. Dev. & Strategic Plan
• Martin Meglasson,
  V-P, Discovery Research
• Pharmaceuticals Inc Ligand,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Steven J Burakoff,
  Director
• Brigette Roberts,
  Director
• Partners L P/Ilbiotechnolog...,
  
• John P Sharp,
  VP Finance and CFO
• Daniel S Loeb,
  Director
• Michael A Rocca,
  Director
• John Groom,
  Director
• Taylor Crouch,
  Sr. V-P, Ops & Pres. Int'l
• Partners L P/Ilbiotechnolog...,
  
• Jeffrey R Perry,
  Director
• Alexander D Cross,
  Director
• William A Petttit,
  Sr. V-P, HR and Administration
• Paul V Maier,
  Sr. V-P, CFO
• Warner R Broaddus,
  V-P, Gen. Counsel & Secy.
• Elizabeth M Greetham,
  Director
• Henry F Blissenbach,
  Director
• Irving S Johnson,
  Director
• Carl C Peck,
  Director
• Eric S Groves,
  V-P, Project Management
• Giambattista Aliprandi,
  Sr. VP, Tech., Sup & Intl Oper
• James J Litalien,
  Sr. V-P, Reg Affairs & Comp.
• David E Robinson,
  President & CEO
• Tod Mertes,
  V-P, Controller & Treasurer
• Jennifer R. Cochran,
  
• Octavio Espinoza,
  Chief Financial Officer
• Martine Zimmermann,
  Director
• Andrew Reardon,
  CLO & Secretary